NIH's $402M Multiyear Funding Shift Is Why Researchers Saw 66% Fewer Grants in Early FY2026. The Accounting Trick Reshaping the Biomedical Pipeline.

The most consequential change to U.S. biomedical research funding in 2026 isn't a new initiative, a policy reversal, or a budget cut in the traditional sense. It is an accounting maneuver — one that the National Institutes of Health has accelerated quietly across the first six months of the fiscal year and that is now showing up as a 66 percent collapse in the number of new grants awarded compared to the same period in 2025.

The mechanism is called "multiyear funding." Instead of obligating one year of a grant's budget at a time and renewing the remaining years through the standard noncompeting continuation process, NIH commits the entire multi-year budget upfront. On paper, a single multiyear award costs the same as a series of annual obligations across the project's lifespan. In a given fiscal year, though, it consumes three to five times more of the appropriated budget than a traditional Year 1 commitment. And because Congress appropriates NIH funding annually, every dollar locked into a multiyear obligation today is a dollar that cannot fund a new award this year.

The scale of the shift is now visible. As of mid-May 2026, NIH had awarded 601 multiyear grants totaling $402 million. At the same point in fiscal year 2025, it had awarded just 162 such grants worth $79 million. At the same point in fiscal year 2024, the figure was 146 grants worth $75 million. The agency has, in other words, more than tripled the dollar volume of multiyear obligations year over year — and the consequence, according to Association of American Universities tracking, is that NIH has issued roughly two-thirds fewer total grant awards in the opening months of FY2026 than it did in the same window of FY2025.

For researchers waiting on R01 paylines, K awards, F-series fellowships, and the broader noncompeting continuation pipeline, the math is brutal. NIH's appropriated extramural pool — roughly $37 billion in distributed grants last fiscal year, drawn from a $47-plus billion total agency budget — does not grow when more of it is committed upfront. It simply funds fewer principal investigators this year.

Why the Shift Hits New Awards Hardest

The mechanics here are worth slowing down on, because they explain why the same total budget can produce dramatically fewer awards in a transition year.

Under traditional NIH practice, a five-year R01 awarded in FY2025 would obligate roughly one-fifth of its budget in FY2025 (Year 1), with the remaining four years moving through noncompeting continuation reviews and being obligated against future fiscal years' appropriations. From a cash perspective, the agency has paid Year 1; from a budget perspective, only Year 1 has consumed FY2025 dollars. A new R01 awarded later in FY2025 can draw from the same pool.

A multiyear obligation works differently. The same five-year R01, obligated as a multiyear award, consumes all five years of budget in FY2025. The grant is fully committed, fully funded, and entirely off the books for the next four years. The researcher receiving it benefits — the funding cannot be cut, deferred, or politically reallocated mid-project. But every dollar locked in is a dollar unavailable for a new award. When the agency does this with 601 grants totaling $402 million in the first half of a fiscal year, the remaining pool for new commitments is meaningfully smaller than it would have been under the traditional approach.

The trajectory of the shift suggests this is not a one-off. In FY2024, NIH obligated $960 million across 1,067 multiyear grants. In FY2025, it obligated $2.2 billion across more than 2,000 such grants — roughly 6 percent of all extramural obligations. If the FY2026 first-half pace holds through September, the agency is on track to obligate $800 million to $1 billion in multiyear awards across the full year, on top of what continuing multiyear commitments already consume.

What Universities Are Seeing on the Ground

The downstream effects are showing up in concrete places. Heather Pierce of the Association of American Medical Colleges has framed the dynamic as forward-funding fewer grants at the cost of leaving "less funding for emerging ideas" — meaning that the labs most exposed to the shift are early-career investigators, K-award recipients transitioning to R01s, and PIs whose first competitive renewal falls into this fiscal year. Lizbet Boroughs of the Association of American Universities has reported that member institutions are reducing PhD admissions in response to the contracted award flow, on the reasoning that bringing in students requires multi-year guarantees of stipend support that the current funding picture cannot underwrite.

For a typical R1 research university, the practical decisions cascade downstream: department chairs hold off on faculty searches, principal investigators delay technician hires, postdoctoral training slots go unfilled, and bridge funding from indirect cost recoveries gets stretched thinner. Universities with large endowments and aggressive internal bridge programs — Harvard, Stanford, the Ivy-Plus tier — can absorb a year or two of this. Mid-tier R1s and minority-serving institutions cannot, and the asymmetry of who can cushion a funding gap shows up in who is still admitting PhD students this cycle and who is not.

The Strategic Picture for Researchers

The first thing applicants should understand is that the shift does not change the underlying merit-review process. Study sections still meet, score sheets still arrive, and percentiles still mean what they have always meant. What changes is the payline — the percentile cutoff below which an institute will actually fund an application. With less money available for new awards, paylines tighten. A score that would have funded comfortably at the 18th percentile in FY2024 may now sit on the bubble at the 10th. The same proposal, with the same review outcome, faces a different funding decision.

The second thing to understand is that multiyear funding, when received, is now a substantially more valuable form of award. A multiyear-funded R01 is functionally insulated from mid-project politics — the money is obligated, the agency cannot pull it back as part of a future appropriations dispute, and the grant administrator's risk profile drops sharply. For senior researchers with established programs, lobbying for multiyear status (where the institute has discretion) is rational. For early-career investigators, the calculus is harder: a five-year multiyear obligation looks great on paper, but the institutes are not handing them out to first-time PIs at the same rate as established labs.

The third strategic implication concerns timing. Researchers planning to submit during the second half of FY2026 should expect tighter paylines than the historical baseline and should plan accordingly: stronger preliminary data, sharper aims, a more deliberate funding diversification strategy that does not assume NIH will be the sole sponsor. Foundations active in the same disease areas — the Howard Hughes Medical Institute, the Chan Zuckerberg Initiative, the Doris Duke Charitable Foundation, the Burroughs Wellcome Fund, and disease-specific foundations like the American Heart Association and Cystic Fibrosis Foundation — become correspondingly more important as gap fillers. Industry-sponsored research and DOD's Congressionally Directed Medical Research Programs, which operate on a separate appropriations cycle and have not adopted NIH's multiyear shift, are similarly worth re-examining as supplements.

How This Connects to the Broader Funding Landscape

The multiyear shift sits inside a wider 2026 contraction. The total number of opportunities posted on grants.gov dropped 33 percent year over year in February 2026, with new posted opportunities down more than 50 percent. NSF, after $8.75 billion in FY2026 appropriations, has restructured its merit-review process and terminated 1,752 grants under DOGE-driven cuts. DOE has issued retention letters on hundreds of Biden-era grants. The cumulative effect, across agencies, is a federal research pool that is smaller, slower to commit, and more politically contested than at any point since the early 2010s sequestration.

What makes the NIH multiyear shift distinctive is that it is not a cut — it is a reallocation of the timing of obligations within a roughly stable appropriation. That makes it harder to push back against politically (no line-item is being eliminated), easier to defend technically (the agency is reducing political risk for funded researchers), and more damaging in the short run for new applicants (fewer dollars chase the same pool of competitive proposals). For researchers building a 2026-2028 funding strategy, treating this as a temporary anomaly is the wrong read. The trajectory from $960 million in FY2024 to a likely $1 billion-plus in FY2026 multiyear obligations is a deliberate institutional shift, not a transient one.

The labs that come out of the next three years in the strongest position will be the ones that diversified early, built foundation relationships before they needed them, and treated the federal research pipeline as one funding source among several rather than the default. That is a different operating posture than most biomedical research groups have maintained since the post-doubling era began in 2003, and it is the one the 2026 numbers are quietly forcing.

For the underlying news report on the latest fiscal year figures, see Granted News. For our running analysis of the broader 2026 federal funding contraction, see Federal Grant Opportunities Plummet 33% in 2026.